SQP33

SQP33 is a chemically-attenuated protodrug of doxorubicin developed by Shasqi, Inc. as the systemic component of the SQ3370 therapeutic system. It consists of doxorubicin modified with a trans-cyclooctene (TCO) moiety and a glycine residue to enhance solubility. SQP33 is designed to remain inactive and significantly less toxic (approximately 82-fold) than conventional doxorubicin until it encounters SQL70, a tetrazine-modified hyaluronic acid biopolymer injected intratumorally. Upon contact, a bioorthogonal click chemistry reaction (inverse electron-demand Diels-Alder) occurs, triggering the local release of active doxorubicin within the tumor microenvironment. This approach, part of Shasqi's Click Activated Protodrugs Against Cancer (CAPAC) platform, aims to increase the therapeutic index of potent chemotherapeutics by minimizing systemic exposure while maximizing local concentration. It is currently being evaluated for the treatment of advanced solid tumors.

Other names

TCO-doxorubicintrans-cyclooctene-modified doxorubicin